"Leukemia, T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
| Descriptor ID |
D015458
|
| MeSH Number(s) |
C04.557.337.428.580 C15.604.515.560.575 C20.683.515.528.582
|
| Concept/Terms |
Leukemia, T-Cell- Leukemia, T-Cell
- Leukemia, T Cell
- Leukemia, Lymphocytic, T-Cell
- Lymphocytic Leukemia, T-Cell
- Leukemia, T-Cell Lymphocytic
- Leukemias, T-Cell Lymphocytic
- Lymphocytic Leukemia, T Cell
- Lymphocytic Leukemias, T-Cell
- T-Cell Lymphocytic Leukemia
- T-Cell Lymphocytic Leukemias
- T-Cell Leukemia
- Leukemias, T-Cell
- T Cell Leukemia
- T-Cell Leukemias
- T-Lymphocytic Leukemia
- Leukemia, T-Lymphocytic
- Leukemias, T-Lymphocytic
- T-Lymphocytic Leukemias
- Leukemia, Lymphocytic, T Cell
- T Lymphocytic Leukemia
- Leukemia, T Lymphocytic
- Leukemias, T Lymphocytic
- Lymphocytic Leukemia, T
- Lymphocytic Leukemias, T
- T Lymphocytic Leukemias
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, T-Cell".
This graph shows the total number of publications written about "Leukemia, T-Cell" by people in this website by year, and whether "Leukemia, T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, T-Cell" by people in Profiles.
-
Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. Leuk Lymphoma. 2014 May; 55(5):1194-7.
-
"Whatever my mother wants": barriers to adequate pain management. J Palliat Med. 2013 Jun; 16(6):709-12.
-
HTLV-2 Tax immortalizes human CD4+ memory T lymphocytes by oncogenic activation and dysregulation of autophagy. J Biol Chem. 2012 Oct 05; 287(41):34683-93.
-
The Notch/Hes1 pathway sustains NF-?B activation through CYLD repression in T cell leukemia. Cancer Cell. 2010 Sep 14; 18(3):268-81.
-
Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant. Pediatr Blood Cancer. 2009 Dec; 53(6):1127-9.
-
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.
-
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008 Jan 01; 111(1):328-37.
-
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res. 2007 Jul; 31(7):939-45.
-
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.
-
Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol. 2006 Apr; 43(2 Suppl 2):S27-34.